Eli Lilly presents new data on Victoza challenger
Novo Nordisk’s U.S. rival, Eli Lilly, has presented positive data for the diabetes drug, Dulaglutide, which analysts and investors see as a serious rival to Novo Nordisk’s GLP-1 success.
by Leonora Beck
Eli Lilly’s GLP-1 analogue, Dulaglutide, is better at controlling blood sugar levels than three other major diabetes products. At least that is what clinical data from three phase III trials, published by the American pharma group the past weekend at the world’s largest diabetes congress held by the American Diabetes Association, indicate.
Allerede abonnent?Log ind her
Læs hele artiklen
Få adgang i 14 dage for 0 kr. Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
